Kawaguchi Y, Miyamoto S, Hajika Y, et al. - Using intermittent continuous glucose monitoring, the efficacy (time in range of glucose level 70–180 mg/dL), safety (time below range level 1 of glucose < 70 mg/dL), glycemic variability changes, therapeutic indices, body mass index and titration periods were compared between multiple daily injection and insulin glargine U100 and lixisenatide (iGlarLixi) combination (iGlarLixi + insulin glulisine; injected once daily [evenings]) therapies.

• Researchers randomly assigned a total of 40 hospitalized patients with type 2 diabetes to receive iGlarLixi + insulin glulisine or the multiple daily injection treatment.

• Per outcomes, iGlarLixi + insulin glulisine combination therapy and multiple daily injection therapy were safe and equally efficacious for glycemic control.

• The combination averted hypoglycemia risk and lowered the number of injections required.